货号:GS40691
Tafasitamab is a humanized monoclonal antibody targeting CD19, a surface protein expressed on B cells. It binds to CD19 and enhances anti-tumor activity through modified Fc engineering to improve antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP). It is approved in combination with lenalidomide for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for autologous stem cell transplant.
武汉迈思生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!
冉凯凯